The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

BioRestorative Reports Positive Phase 2 Clinical Data for BRTX-100 Stem Cell Therapy

Key Facts

1BioRestorative Therapies announced positive blinded Phase 2 data for its stem cell-based product BRTX-100.

2Data showed 50% or more of patients reported >50% improvement in key pain and function scales.

3No adverse events related to dose-limiting toxicities associated with mesenchymal stem cells were reported.

Create Free Account

BioRestorative Therapies announced positive blinded Phase 2 clinical trial results for its stem cell-based product, BRTX-100. The treatment targets chronic lumbar disc disease using hypoxic-cultured mesenchymal stem cells to improve patient outcomes. According to the reported data, 50% or more of patients achieved a significant improvement of over 50% in key pain and functional metrics. Importantly, the trial reported no adverse events related to dose-limiting toxicities associated with the mesenchymal stem cells. This milestone marks a critical step forward in the company's clinical development pipeline for chronic back pain. Investors view these results as a strong validation of the product's safety and efficacy profile within the biotech sector.